Literature DB >> 27257835

Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease.

A Gabriella Wernicke1, Andrew W Smith2, Shoshana Taube1, Menachem Z Yondorf1, Bhupesh Parashar1, Samuel Trichter1, Lucy Nedialkova1, Albert Sabbas1, Paul Christos3, Rohan Ramakrishna4, Susan C Pannullo4, Philip E Stieg4, Theodore H Schwartz4.   

Abstract

OBJECTIVE Managing patients whose intraparenchymal brain metastases recur after radiotherapy remains a challenge. Intraoperative cesium-131 (Cs-131) brachytherapy performed at the time of neurosurgical resection may represent an excellent salvage treatment option. The authors evaluated the outcomes of this novel treatment with permanent intraoperative Cs-131 brachytherapy. METHODS Thirteen patients with 15 metastases to the brain that recurred after stereotactic radiosurgery and/or whole brain radiotherapy were treated between 2010 and 2015. Stranded Cs-131 seeds were placed as a permanent volume implant. Prescription dose was 80 Gy at 5-mm depth from the resection cavity surface. The primary end point was resection cavity freedom from progression (FFP). Resection cavity freedom from progression (FFP), regional FFP, distant FFP, median survival, overall survival (OS), and toxicity were assessed. RESULTS The median duration of follow-up after salvage treatment was 5 months (range 0.5-18 months). The patients' median age was 64 years (range 51-74 years). The median resected tumor diameter was 2.9 cm (range 1.0-5.6 cm). The median number of seeds implanted was 19 (range 10-40), with a median activity per seed of 2.25 U (range 1.98-3.01 U) and median total activity of 39.6 U (range 20.0-95.2 U). The 1-year actuarial local FFP was 83.3%. The median OS was 7 months, and 1-year OS was 24.7%. Complications included infection (3), pseudomeningocele (1), seizure (1), and asymptomatic radionecrosis (RN) (1). CONCLUSIONS After failure of prior irradiation of brain metastases, re-irradiation with intraoperative Cs-131 brachytherapy implants provides durable local control and limits the risk of RN. The authors' initial experience demonstrates that this treatment approach is well tolerated and safe for patients with previously irradiated tumors after failure of more than 1 radiotherapy regimen and that it results in excellent response rates and minimal toxicity.

Entities:  

Keywords:  ADC = apparent diffusion coefficient; FFP = freedom from progression; OS = overall survival; QOL = quality of life; RN = radionecrosis; RPA = recursive partitioning analysis; SRS = stereotactic radiosurgery; WBRT = whole brain radiotherapy; brachytherapy; cesium-131; metastases; oncology; radiation; re-irradiation; recurrence

Mesh:

Substances:

Year:  2016        PMID: 27257835     DOI: 10.3171/2016.3.JNS152836

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

1.  Resection Cavity Contraction Effects in the Use of Radioactive Sources (1-25 versus Cs-131) for Intra-Operative Brain Implants.

Authors:  Dae Y Han; Lijun Ma; Steve Braunstein; David Raleigh; Patricia K Sneed; Michael McDermott
Journal:  Cureus       Date:  2018-01-16

Review 2.  Brachytherapy for central nervous system tumors.

Authors:  Evan D Bander; Jonathan P S Knisely; Theodore H Schwartz
Journal:  J Neurooncol       Date:  2022-05-11       Impact factor: 4.130

Review 3.  The role of cesium-131 brachytherapy in brain tumors: a scoping review of the literature and ongoing clinical trials.

Authors:  Paolo Palmisciano; Ali S Haider; Kishore Balasubramanian; Randy S D'Amico; Alla Gabriella Wernicke
Journal:  J Neurooncol       Date:  2022-06-13       Impact factor: 4.506

4.  Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors.

Authors:  Dilini S Pinnaduwage; Shiv P Srivastava; Xiangsheng Yan; Shyam Jani; David G Brachman; Stephen P Sorensen
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  Salvage brachytherapy for multiply recurrent metastatic brain tumors: A matched case analysis.

Authors:  Kyle C Wu; Jonathan M Cantalino; Edward C Dee; Liangge Hsu; Thomas C Harris; Bhupendra Rawal; Parikshit R Juvekar; Michael A Mooney; Ian F Dunn; Ayal A Aizer; Phillip M Devlin; Wenya Linda Bi
Journal:  Neurooncol Adv       Date:  2022-04-22

6.  Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study.

Authors:  Michael A Mooney; Wenya Linda Bi; Jonathan M Cantalino; Kyle C Wu; Thomas C Harris; Lucas L Possatti; Parikshit Juvekar; Liangge Hsu; Ian F Dunn; Ossama Al-Mefty; Phillip M Devlin
Journal:  J Neurooncol       Date:  2019-11-19       Impact factor: 4.130

Review 7.  Evolving Strategies to Potentially Further Optimize Surgical Interventions in Brain Cancer.

Authors:  Bindi B Parikh; Elizabeth C Neil
Journal:  Curr Oncol Rep       Date:  2020-03-06       Impact factor: 5.075

Review 8.  The role of brachytherapy in the management of brain metastases: a systematic review.

Authors:  Bhargava Chitti; Sharad Goyal; Jonathan H Sherman; Anthony Caputy; Mehrdad Sarfaraz; Gizem Cifter; Hamid Aghdam; Yuan James Rao
Journal:  J Contemp Brachytherapy       Date:  2020-02-28

9.  Permanent Interstitial Cesium-131 Brachytherapy in Treating High-Risk Recurrent Head and Neck Cancer: A Prospective Pilot Study.

Authors:  Michael Kharouta; Chad Zender; Tarun Podder; Rod Rezaee; Pierre Lavertu; Nicole Fowler; Jason Thuener; Shawn Li; Kate Clancy; Zhengzheng Xu; Min Yao
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

10.  Surgical Outcomes of Novel Collagen Tile Cesium Brachytherapy for Recurrent Intracranial Tumors at a Tertiary Referral Center.

Authors:  Kwanza T Warren; Andrew Boucher; David P Bray; Sean Dresser; Jim Zhong; Hiu-Kuo Shu; Jeffrey Olson; Kimberly Hoang
Journal:  Cureus       Date:  2021-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.